Decentralized clinical trials (DCTs): A few ethical considerations

Decentralized clinical trials (DCTs) are studies in which the need for patients to physically access hospital-based trial sites is reduced or eliminated. The CoViD-19 pandemic has caused a significant increase in DCT: a survey shows that 76% of pharmaceutical companies, device manufacturers, and Contract Research Organizations adopted decentralized techniques during the early phase of the pandemic. The implementation of DCTs relies on the use of digital tools such as e-consent, apps, wearable devices, Electronic Patient-Reported Outcomes (ePRO), telemedicine, as well as on moving trial activities to the patient's home (e.g., drug delivery) or to local healthcare settings (i.e., community-based diagnosis and care facilities). DCTs adapt to patients' routines, allow patients to participate regardless of where they live by removing logistical barriers, offer better access to the study and the investigational product, and permit the inclusion of more diverse and more representative populations. The feasibility and quality of DCTs depends on several requirements including dedicated infrastructures and staff, an adequate regulatory framework, and partnerships between research sites, patients and sponsors. The evaluation of Ethics Committees (ECs) is crucial to the process of innovating and digitalizing clinical trials: adequate assessment tools and a suitable regulatory framework are needed for evaluation by ECs. DCTs also raise issues, many of which are of considerable ethical significance. These include the implications for the relationship between patients and healthcare staff, for the social dimension of the patient, for data integrity (at the source, during transmission, in the analysis phase), for personal data protection, and for the possible risks to health and safety. Despite their considerable growth, DCTs have only received little attention from bioethicists. This paper offers a review on some ethical implications and requirements of DCTs in order to encourage further ethical reflection on this rapidly emerging field.

[1]  J. Yang,et al.  Blockchain for applications of clinical trials: Taxonomy, challenges, and future directions , 2022, IET Commun..

[2]  P. Wicks,et al.  What role can decentralized trial designs play to improve rare disease studies? , 2022, Orphanet Journal of Rare Diseases.

[3]  G. van Thiel,et al.  Opportunities and Challenges for Decentralized Clinical Trials: European Regulators’ Perspective , 2022, Clinical pharmacology and therapeutics.

[4]  G. van Thiel,et al.  Ethics review of decentralized clinical trials (DCTs): results of a mock ethics review. , 2022, Drug discovery today.

[5]  T. MacDonald,et al.  A systematic review of methods used to conduct decentralised clinical trials , 2021, British journal of clinical pharmacology.

[6]  P. Wicks,et al.  Resilient design: decentralized trials recovered faster from the impact of COVID-19 than traditional site-based designs , 2021, Expert review of medical devices.

[7]  Marcus A. Banks Core Concept: In the wake of COVID-19, decentralized clinical trials move to center stage , 2021, Proceedings of the National Academy of Sciences.

[8]  A. Boorsma,et al.  Stakeholder Perspectives on Barriers and Facilitators for the Adoption of Virtual Clinical Trials: Qualitative Study , 2021, Journal of medical Internet research.

[9]  A. Newman,et al.  Remote Research and Clinical Trial Integrity During and After the Coronavirus Pandemic. , 2021, JAMA.

[10]  Gail A. Van Norman,et al.  Decentralized Clinical Trials , 2021, JACC. Basic to translational science.

[11]  R. Plummer,et al.  Reimagining Global Oncology Clinical Trials for the Postpandemic Era: A Call to Arms , 2020, JCO global oncology.

[12]  Zachary P. Hallinan,et al.  Learning from patient and site perspectives to develop better digital health trials: Recommendations from the Clinical Trials Transformation Initiative , 2020, Contemporary clinical trials communications.

[13]  J. Zibert,et al.  High adherence and low dropout rate in a virtual clinical study of atopic dermatitis through weekly reward-based personalized genetic lifestyle reports , 2020, PloS one.

[14]  A. Forrest,et al.  Legal, Regulatory, and Practical Issues to Consider When Adopting Decentralized Clinical Trials: Recommendations From the Clinical Trials Transformation Initiative , 2019, Therapeutic Innovation & Regulatory Science.

[15]  Sean Khozin,et al.  Decentralized Trials in the Age of Real‐World Evidence and Inclusivity in Clinical Investigations , 2019, Clinical pharmacology and therapeutics.

[16]  Patrick Martin,et al.  Using Blockchain Technology to Manage Clinical Trials Data: A Proof-of-Concept Study , 2018, JMIR medical informatics.

[17]  Nadir Weibel,et al.  Ethical and regulatory challenges of research using pervasive sensing and other emerging technologies: IRB perspectives , 2017, AJOB empirical bioethics.

[18]  Erik Schultes,et al.  The FAIR Guiding Principles for scientific data management and stewardship , 2016, Scientific Data.

[19]  Gloria M. Miele,et al.  Using e-technologies in clinical trials. , 2015, Contemporary clinical trials.

[20]  S. Cummings,et al.  Web-based trial to evaluate the efficacy and safety of tolterodine ER 4 mg in participants with overactive bladder: REMOTE trial. , 2014, Contemporary clinical trials.

[21]  A. Barratt,et al.  Internet trials: participant experiences and perspectives , 2012, BMC Medical Research Methodology.

[22]  P. Cardon,et al.  A qualitative study. , 2001 .

[23]  K Ely-Pierce,et al.  A call to arms. , 1999, JONA'S healthcare law, ethics and regulation.